Strengths

ROIC of 9.0% indicates Teva is generating acceptable returns on capital, but peers with cleaner balance sheets and higher-margin portfolios typically convert capital into value more efficiently.

Teva’s scale in generics and specialty medicines supports broad market access, yet peer leaders with more innovative mixes usually sustain stronger pricing power and margin resilience.

The company’s cash conversion cycle is long at 94.6 days, but its established distribution footprint still helps it operate at a scale many smaller peers cannot match.

Teva’s restructuring progress has improved operating discipline, although peer comparisons remain constrained by the absence of a clearly superior margin profile in the provided metrics.

Weaknesses

Net debt to EBITDA of 4.26x leaves Teva more leveraged than many large-cap pharma peers, limiting financial flexibility and increasing sensitivity to earnings volatility.

A current ratio of 0.88 and quick ratio of 0.67 indicate weaker near-term liquidity than stronger peers, which typically maintain more comfortable working-capital buffers.

The 94.6-day cash conversion cycle ties up cash for longer than better-run peers, reducing free-cash-flow efficiency and constraining reinvestment capacity.

Debt to equity of 2.16x signals a heavier capital structure than peers with stronger balance-sheet positioning, which can weigh on valuation and strategic optionality.

Opportunities

Teva can improve peer-relative positioning by continuing deleveraging, because lower leverage would narrow the gap versus better-capitalized competitors and reduce financing risk.

Further working-capital optimization could shorten the cash conversion cycle, improving cash generation relative to peers that already operate with tighter inventory and receivables control.

If specialty-product execution strengthens, Teva could lift returns above generic-heavy peers, since higher-value mix typically supports better margin durability.

Portfolio simplification and cost discipline could enhance capital efficiency, allowing Teva to close the gap with peers that already translate scale into stronger profitability.

Threats

Generic-drug pricing pressure remains a structural threat because peers with more differentiated portfolios can defend margins better than Teva’s more exposed mix.

High leverage makes Teva more vulnerable than less indebted peers to refinancing costs and earnings disappointments, which can amplify downside in a weaker operating cycle.

Liquidity constraints increase execution risk, since peers with stronger current and quick ratios can absorb shocks more easily and preserve operating continuity.

Long cash conversion cycles leave Teva less agile than peers in funding inventory and receivables, which can matter if demand softens or supplier terms tighten.

Overall Score

Teva’s scale and acceptable capital returns are offset by weaker leverage and liquidity than peers, leaving its structural positioning moderate overall.